Prograf
Company: Fujisawa Healthcare
Approval Status: Approved April 1997
Treatment for: kidney transplant rejection
Areas: Endocrinology; Nephrology/Urology
| General Information | Side Effects |
General Information
Prograf has been approved for use as an immunosuppressive for the prevention of organ rejection in kidney transplant recipients. It is manufactured in capsule and injection form. Previously, Prograf has been used since 1994 for the prophylaxis of rejection in liver transplants.
Side Effects
Adverse effects associated with Prograf include tremor, hypertension, hypophosphatemia, infection, creatinine increase, headache, and diarrhea. New onset post-transplant diabetes mellitus (PTDM) was seen in 20% of Prograf-treated kidney transplant patients. The percentage of PTDM patients that remained insulin dependent at the two year post-transplant mark declined to 11%.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
